Metformina Aurovitas (Metformin Hydrochloride)

Metformin primarily inhibits mitochondrial complex I, which reduces the liver's production of glucose. It also enhances peripheral uptake of glucose by muscle and fat cells and improves insulin sensitivity, thereby lowering overall blood sugar without directly stimulating insulin release.

The exact dose of Metformina Aurovitas is determined by the prescribing clinician based on the patient’s renal function, glycaemic targets, and overall health status. Dosage adjustments are made individually, and patients should follow the prescriber’s instructions precisely.

Safety of metformin during pregnancy or lactation should be evaluated by a healthcare professional. While some guidelines allow its use when benefits outweigh risks, the decision must be individualized, and patients should discuss any concerns with their prescriber.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and necessary import documentation.

Metformina Aurovitas belongs to the biguanide class, differing from sulfonylureas, DPP‑4 inhibitors, or SGLT2 inhibitors. Unlike insulin‑secretagogues, metformin does not cause direct insulin release, reducing hypoglycaemia risk. It is often first‑line therapy due to its efficacy, weight‑neutral profile, and cardiovascular benefits.

Store Metformina Aurovitas at ambient temperature, preferably below 25 °C, in the original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Metformina Aurovitas is taken orally, usually with meals to minimise gastrointestinal discomfort. The tablets should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed by a healthcare professional.

The most serious adverse effect is lactic acidosis, a rare but life‑threatening condition that can occur in patients with severe renal impairment, liver disease, or excessive alcohol intake. Prompt medical attention is required if symptoms such as rapid breathing, muscle pain, or abdominal discomfort develop.

Metformina Aurovitas is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), acute or chronic metabolic acidosis, known hypersensitivity to metformin, or those receiving radiographic contrast studies without appropriate discontinuation.